UBS analysts maintained a Buy rating for Alvotech SA (NASDAQ:ALVO) with a steady price target of $18.00, representing a 41% ...

The second part of our conversation with Craig Burton, MBA, executive director of the Biosimilars Council, a trade and ...

Amgen's Wezlana leading ustekinumab biosimilar launches, potentially driving savings and access, as highlighted by Dracey ...

After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...

AbbVie Inc . (NYSE:ABBV), currently trading at $190.14, has demonstrated resilience and strategic foresight as it navigates the loss of exclusivity for its blockbuster drug Humira. The ...

Investors are also waiting to see how generic competition shakes out for Stelara. Using AbbVie's (ABBV) Humira as a guide, the company and analysts alike see potential for a muted impact.

Investors are also waiting to see how generic competition shakes out for Stelara. Using AbbVie's (ABBV) Humira as a guide, the company and analysts alike see potential for a muted impact. Humira ...

In terms of how Stelara’s loss of exclusivity is likely to play out, “we’ve talked about the Humira erosion curve being probably the best thing to model,” Jennifer Taubert, J&J’s ...

STELARA biosimilar competition to accelerate; HUMIRA erosion curve remains the best proxy. Negative impact of Part D re-design, as a percent to sales, will be consistently applied throughout the year.

Investors are watching biosimilar competition with immunology drug Stelara, which extended to the key US market in January. We assume a more than $3 billion decline in global Stelara sales in 2025.